BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 28674081)

  • 1. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation.
    Harhouri K; Navarro C; Depetris D; Mattei MG; Nissan X; Cau P; De Sandre-Giovannoli A; Lévy N
    EMBO Mol Med; 2017 Sep; 9(9):1294-1313. PubMed ID: 28674081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MG132 Induces Progerin Clearance and Improves Disease Phenotypes in HGPS-like Patients' Cells.
    Harhouri K; Cau P; Casey F; Guedenon KM; Doubaj Y; Van Maldergem L; Mejia-Baltodano G; Bartoli C; De Sandre-Giovannoli A; Lévy N
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
    Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
    Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
    Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
    Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
    Gabriel D; Roedl D; Gordon LB; Djabali K
    Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
    Chen X; Yao H; Andrés V; Bergo MO; Kashif M
    Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells.
    Aveleira CA; Ferreira-Marques M; Cortes L; Valero J; Pereira D; Pereira de Almeida L; Cavadas C
    J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1073-1078. PubMed ID: 32012215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of LMNA splicing as a strategy to treat prelamin A diseases.
    Lee JM; Nobumori C; Tu Y; Choi C; Yang SH; Jung HJ; Vickers TA; Rigo F; Bennett CF; Young SG; Fong LG
    J Clin Invest; 2016 Apr; 126(4):1592-602. PubMed ID: 26999604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A conserved splicing mechanism of the LMNA gene controls premature aging.
    Lopez-Mejia IC; Vautrot V; De Toledo M; Behm-Ansmant I; Bourgeois CF; Navarro CL; Osorio FG; Freije JM; Stévenin J; De Sandre-Giovannoli A; Lopez-Otin C; Lévy N; Branlant C; Tazi J
    Hum Mol Genet; 2011 Dec; 20(23):4540-55. PubMed ID: 21875900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype.
    Lee SJ; Jung YS; Yoon MH; Kang SM; Oh AY; Lee JH; Jun SY; Woo TG; Chun HY; Kim SK; Chung KJ; Lee HY; Lee K; Jin G; Na MK; Ha NC; Bárcena C; Freije JM; López-Otín C; Song GY; Park BJ
    J Clin Invest; 2016 Oct; 126(10):3879-3893. PubMed ID: 27617860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
    Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
    Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
    Kreienkamp R; Croke M; Neumann MA; Bedia-Diaz G; Graziano S; Dusso A; Dorsett D; Carlberg C; Gonzalo S
    Oncotarget; 2016 May; 7(21):30018-31. PubMed ID: 27145372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel mitigates structural alterations and cardiac conduction system defects in a mouse model of Hutchinson-Gilford progeria syndrome.
    Macías Á; Díaz-Larrosa JJ; Blanco Y; Fanjul V; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; da Rocha AM; Ponce-Balbuena D; Allan A; Filgueiras-Rama D; Jalife J; Andrés V
    Cardiovasc Res; 2022 Jan; 118(2):503-516. PubMed ID: 33624748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.
    Fong LG; Vickers TA; Farber EA; Choi C; Yun UJ; Hu Y; Yang SH; Coffinier C; Lee R; Yin L; Davies BS; Andres DA; Spielmann HP; Bennett CF; Young SG
    Hum Mol Genet; 2009 Jul; 18(13):2462-71. PubMed ID: 19376814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splicing-directed therapy in a new mouse model of human accelerated aging.
    Osorio FG; Navarro CL; Cadiñanos J; López-Mejía IC; Quirós PM; Bartoli C; Rivera J; Tazi J; Guzmán G; Varela I; Depetris D; de Carlos F; Cobo J; Andrés V; De Sandre-Giovannoli A; Freije JM; Lévy N; López-Otín C
    Sci Transl Med; 2011 Oct; 3(106):106ra107. PubMed ID: 22030750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated prelamin A expression in HGPS-like patients: a transcriptional study.
    Barthélémy F; Navarro C; Fayek R; Da Silva N; Roll P; Sigaudy S; Oshima J; Bonne G; Papadopoulou-Legbelou K; Evangeliou AE; Spilioti M; Lemerrer M; Wevers RA; Morava E; Robaglia-Schlupp A; Lévy N; Bartoli M; De Sandre-Giovannoli A
    Eur J Hum Genet; 2015 Aug; 23(8):1051-61. PubMed ID: 25649378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.